Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atosiban for endometriosis-associated pain
NL-OMON47936Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atosiban in endometriosis, sponsored by Radboud University Medical Center. Primary endpoint: Reduction in pain score on a visual analog scale. Started Mar 2022; status: recruiting.
02
Drugs
atosiban
03
Conditions
endometriosis
Beyond the preview
Go deeper on NL-OMON47936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47936.